Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
2.585 EUR | +3.82% | +6.82% | +79.51% |
May. 29 | NFL Biosciences: study with CEA presented at congress | CF |
May. 21 | NFL Biosciences receives positive feedback from the FDA | CF |
Business Summary
At the end of 2023, the company has one product in phase II/III clinical development (NFL-101) and two products in preclinical development (NFL-201 for the treatment of cannabis addiction and NFL-301 for alcohol reduction).
Managers
Managers | Title | Age | Since |
---|---|---|---|
Bruno Lafont
FOU | Founder | - | 06-08-31 |
Ignacio Faus
CEO | Chief Executive Officer | - | 21-05-18 |
Guillaume Audema
DFI | Director of Finance/CFO | - | - |
Chief Tech/Sci/R&D Officer | - | - |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Yannick Plétan
BRD | Director/Board Member | - | 21-05-18 |
Ignacio Faus
CEO | Chief Executive Officer | - | 21-05-18 |
Bruno Lafont
FOU | Founder | - | 06-08-31 |
Francis Ahner
BRD | Director/Board Member | - | 21-05-18 |
Michel Huc
BRD | Director/Board Member | - | 21-05-18 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 7,606,769 | 5,182,266 ( 68.13 %) | 0 | 68.13 % |
Company contact information
NFL Biosciences SAS
199 rue Hélène Boucher
34170, Castelnau-le-Lez
+33 4 11 93 76 67
http://www.nflbiosciences.comSector
Chiffre d''affaires - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+79.51% | 25.96M | |
+18.77% | 125B | |
+14.05% | 108B | |
-7.16% | 23.64B | |
+3.03% | 22.39B | |
-11.39% | 17.78B | |
-41.74% | 16.43B | |
-13.47% | 16.34B | |
+2.23% | 13.56B | |
+27.13% | 11.59B |
- Stock Market
- Equities
- ALNFL Stock
- Company NFL Biosciences